Inhibikase Therapeutics Inc (IKT) — Financial Flexibility Index
Inhibikase Therapeutics Inc (IKT) has a Financial Flexibility Index of -1.51x as of September 2025. Free cash flow of $-10.14 Million (operating CF $-10.59 Million minus capex $452.02K) represents -2% of total liabilities ($6.70 Million). Check IKT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inhibikase Therapeutics Inc Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Inhibikase Therapeutics Inc across 9 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Inhibikase Therapeutics Inc.
Annual Financial Flexibility Index for Inhibikase Therapeutics Inc (2016–2024)
Year-by-year free cash flow to debt coverage for Inhibikase Therapeutics Inc. Explore IKT debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -5.13x | $-19.15 Million | $-19.15 Million | $3.73 Million | ▼ -0.1% |
| 2023 | -5.12x | $-18.07 Million | $-18.09 Million | $3.53 Million | ▼ -16.8% |
| 2022 | -4.39x | $-17.11 Million | $-17.35 Million | $3.90 Million | ▼ -24.4% |
| 2021 | -3.53x | $-14.30 Million | $-14.30 Million | $4.05 Million | ▼ -1460.7% |
| 2020 | -0.23x | $-1.13 Million | $-1.13 Million | $5.00 Million | ▼ -202.4% |
| 2019 | -0.07x | $-338.29K | $-338.29K | $4.53 Million | ▼ -137.9% |
| 2018 | 0.20x | $714.99K | $714.99K | $3.62 Million | ▲ +369.4% |
| 2017 | -0.07x | $-126.39K | $-126.39K | $1.73 Million | ▼ -275.0% |
| 2016 | -0.02x | $-29.57K | $-29.57K | $1.51 Million | — |